BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 17563395)

  • 1. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
    Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
    J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
    Aihara T; Takatsuka Y; Ohsumi S; Aogi K; Hozumi Y; Imoto S; Mukai H; Iwata H; Watanabe T; Shimizu C; Nakagami K; Tamura M; Ito T; Masuda N; Ogino N; Hisamatsu K; Mitsuyama S; Abe H; Tanaka S; Yamaguchi T; Ohashi Y
    Breast Cancer Res Treat; 2010 Jun; 121(2):379-87. PubMed ID: 20390343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
    J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
    Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
    Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
    J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
    Dubsky PC; Jakesz R; Mlineritsch B; Pöstlberger S; Samonigg H; Kwasny W; Tausch C; Stöger H; Haider K; Fitzal F; Singer CF; Stierer M; Sevelda P; Luschin-Ebengreuth G; Taucher S; Rudas M; Bartsch R; Steger GG; Greil R; Filipcic L; Gnant M
    J Clin Oncol; 2012 Mar; 30(7):722-8. PubMed ID: 22271481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
    Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A;
    J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
    Cella D; Fallowfield L; Barker P; Cuzick J; Locker G; Howell A;
    Breast Cancer Res Treat; 2006 Dec; 100(3):273-84. PubMed ID: 16944295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
    J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
    Goss PE; Ingle JN; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Tu D
    J Clin Oncol; 2008 Apr; 26(12):1948-55. PubMed ID: 18332475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
    Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
    J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Clack G; Bianco AR;
    J Obstet Gynaecol; 2010; 30(6):596-604. PubMed ID: 20701510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
    ; Buzdar A; Howell A; Cuzick J; Wale C; Distler W; Hoctin-Boes G; Houghton J; Locker GY; Nabholtz JM
    Lancet Oncol; 2006 Aug; 7(8):633-43. PubMed ID: 16887480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.